Outpatient immunosuppressive drugs under Medicare

Office of Technology Assessment
Record ID 31995000185
Authors' objectives:

To assess alternatives to the current Medicare policy of paying for only one year of post-transplant outpatient immunosuppressive drugs for most Medicare patients.

Authors' results and conclusions: Medicare covers over half of all organ transplants. Between 13 and 43 percent of the Medicare transplant population have no private insurance to supplement their Medicare benefits. Limiting coverage to one year may cause financial hardship for some of the those individuals.
Authors' recommendations: OTA presents 3 alternative policy options for Medicare coverage of immunosuppressive drugs and 4 options regarding payment methods for these drugs. Other output or dissemination activity: Policy subsequently changed to 3-year coverage of these drugs.
Authors' methods: Review
Project Status: Completed
Year Published: 1991
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Immunosuppression Therapy
  • Immunosuppressive Agents
  • Insurance, Health
  • Medicare
  • Organ Transplantation
Organisation Name: U. S. Congress. Office of Technology Assessment
Copyright: Office of Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.